FDA panel discusses hip protocols
This article was originally published in Clinica
Industry representatives recommend that the US FDA should not require more than a two-year follow-up in clinical trials for new or novel hip systems. The Health Industry Manufacturers Association and the Orthopaedic Surgical Manufacturers Association aired their views on proposed changes to clinical protocols at the agency's Orthopaedic and Rehabilitation Devices Advisory Panel on June 12th.
You may also be interested in...
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.